enkemm
$INKT The total treatment cost decreases dramatically when a patient avoids mechanical ventilation or only requires it for a very short duration, and the illness resolves within 7 to 14 days.
Because intensive care costs are heavily tied to time spent on life support, shortening or eliminating the ventilation window removes the primary drivers of ARDS expense. An ARDS case that resolves without invasive mechanical ventilation generally mirrors the cost of a standard, uncomplicated pneumonia or acute respiratory infection hospitalization. Globally, this shifts the total cost down to a baseline range of $8,000 to $20,000, representing a 70% to 85% reduction in total resource expenditure.
Thus...INKT charging 30,000 to 60,000 per patient treatment would save insurance companies hundreds of thousands of dollars in initial and follow up care. 120,000 cases a year in the US...3 million worldwide. Currently, no approved treatment. You tell me what T-797 is worth....
Pg2
6

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault36.jpg)